1. In Vivo
  2. >>Global Vision

China’s Cancer Market Is Evolving Fast, Four Multinationals Dominate

 
• By Mainbayar Badarch

In the Chinese pharmaceutical market, sales of anti-tumor drugs have been showing a steady growth trend in recent years as cancer patient numbers continue to rise.

China flag healthcare
• Source: Shutterstock

In 2020, the number of new cancer cases in China reached 4.6 million, accounting for about a quarter of the global cancer cases. Of which about 1.5 million were advanced cancer patients. Affected by population aging, environmental pollution and unhealthy lifestyles, the number of new cancer cases in China will further increase to 5 million by 2024, which indicates the growing demand for anticancer drugs. China’s anti-tumor drug market is booming, and the market size has increased from CNY139.4bn in 2017 to CNY197.5bn ($28.3bn) in 2020, with a compound annual growth rate of 12.3%. It is expected to reach CHY326bn in 2023.

In recent years, anti-tumor treatment targets have emerged in an endless stream, and related targeted drugs have been innovated, which...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Global Vision

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.